Sean McLintock

Sean McLintock is a Founding Partner at Neo Kuma Ventures based in London, UK. He co-founded the venture capital firm in 2019 to deploy over £10 million across seed to Series C funding rounds in the emerging psychedelic healthcare sector. His investment portfolio includes early-stage stakes in Atai Life Sciences, which partially owns the Nasdaq-listed Compass Pathways following its $127 million initial public offering, alongside Beckley Psytech and Bright Minds. Before launching this investment fund, McLintock worked at the Google Ventures-backed technology company Andela and co-founded the United Kingdom-based consumer beverage brand ThreeDots. He holds a Master's degree in Global Thought from Columbia University and a Bachelor of Laws from Utrecht University. His current focus remains on advancing clinical research and commercializing biotechnology solutions for mental health conditions like depression and PTSD.